Basal C-peptide in the discrimination of type I from type II diabetes
- PMID: 6751738
- DOI: 10.2337/diacare.4.6.616
Basal C-peptide in the discrimination of type I from type II diabetes
Abstract
Basal serum C-peptide concentrations in diabetic patients showed two groups. Diabetic patients with low C-peptide levels (less than or equal to 0.16 nmol/L) have clinical characteristics of type I diabetes, and all were on insulin therapy. With long duration of diabetes, an increasing proportion had undetectable C-peptide. Diabetic patients with high C-peptide levels (greater than 0.16 nmol/L) resemble type II diabetes. In this group 30% were on insulin therapy but duration of known disease was not associated with any decline in the high basal C-peptide levels. The small proportion of diabetic patients with basal serum C-peptide in the range of 0.17-0.32 nmol/L have indeterminate status.
Similar articles
-
Significance of spontaneous ketonuria and serum C-peptide levels in obese type II diabetic patients.Diabetes Care. 1984 Sep-Oct;7(5):442-6. doi: 10.2337/diacare.7.5.442. Diabetes Care. 1984. PMID: 6389058
-
Recovery from decompensated non-insulin-dependent diabetes mellitus: studies of C-peptide secretion.Diabetes Care. 1981 May-Jun;4(3):354-9. doi: 10.2337/diacare.4.3.354. Diabetes Care. 1981. PMID: 7047111
-
Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.J Vet Intern Med. 1996 May-Jun;10(3):116-22. doi: 10.1111/j.1939-1676.1996.tb02042.x. J Vet Intern Med. 1996. PMID: 8743209
-
C-peptide measurement and its clinical usefulness: a review.Ann Clin Biochem. 1981 Jul;18(Pt 4):200-6. doi: 10.1177/000456328101800402. Ann Clin Biochem. 1981. PMID: 7025733 Review. No abstract available.
-
[C-peptide measurement in the classification of diabetes mellitus and in the assessment of requirements for insulin treatment].Ugeskr Laeger. 1990 Feb 26;152(9):588-93. Ugeskr Laeger. 1990. PMID: 2408222 Review. Danish.
Cited by
-
Discrimination of type I from insulin-treated type II diabetic patients by C-peptide measurement.Acta Diabetol Lat. 1986 Oct-Dec;23(4):345-50. doi: 10.1007/BF02582068. Acta Diabetol Lat. 1986. PMID: 3564834
-
Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.Front Endocrinol (Lausanne). 2022 Apr 28;13:871660. doi: 10.3389/fendo.2022.871660. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35574023 Free PMC article.
-
Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents.Ann Pediatr Endocrinol Metab. 2014 Jun;19(2):80-5. doi: 10.6065/apem.2014.19.2.80. Epub 2014 Jun 30. Ann Pediatr Endocrinol Metab. 2014. PMID: 25077090 Free PMC article.
-
Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes.Acta Diabetol. 2025 Jun 5. doi: 10.1007/s00592-025-02537-9. Online ahead of print. Acta Diabetol. 2025. PMID: 40471289
-
Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature.BMJ Open. 2015 Nov 2;5(11):e009088. doi: 10.1136/bmjopen-2015-009088. BMJ Open. 2015. PMID: 26525723 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical